Addressing Gaps in Knowledge of the Optimal Approach to Managing Myelofibrosis

Myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocytopenia, affect approximately 13,000, 134,000, and 148,000 individuals in the United States, respectively. Due to difficulties in identifying the disease, low disease prevalence, a complicated symptom profile, differences in patient and provider perspectives regarding symptom burden and treatment goals, and a lack of effective and tolerable therapies, there is confusion over the optimal approach to t...
Continue reading

Evaluating Symptoms and Treatment Options for Myelofibrosis: Alice Lynn, ANP, and Dawn Urbanovsky, RN, BSN, OCN®

Myelofibrosis, a myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, and extramedullary hematopoiesis, is a very challenging disease to treat, with patients experiencing progressive symptoms that can negatively impact their quality of life. In this excerpt of the transcript from their nursing continuing professional development (NCPD)-approved activity, Nursing Management of Myelofibrosis: Controlling Symptoms and Optimizing Patient Quality of Life, Alice Lynn, ANP, an...
Continue reading

Fedratinib for Improved Quality of Life in Myelofibrosis With Ruben Mesa, MD

Patients with myelofibrosis can experience debilitating symptoms that negatively impact their quality of life. In the phase 3 JAKARTA trial, a team of researchers led by Ruben Mesa, MD, the Director of MD Anderson Cancer Center at the University of Texas, San Antonio, found that fedratinib, an oral JAK2 inhibitor, decreased symptom severity and markedly improved quality of life in patients with intermediate- or high-risk primary or secondary myelofibrosis. Dr. Mesa presented the results of the t...
Continue reading

When Should Ruxolitinib Be Used for Myelofibrosis or PV? With Srdan Verstovsek, MD, PhD

Myelofibrosis, a rare myeloproliferative neoplasm, can cause severe anemia, splenomegaly, and debilitating symptoms. It can present either as a primary condition or as a secondary condition following the transformation of essential thrombocythemia or polycythemia vera (PV), a slow-growing blood cancer in which the bone marrow produces an excess of red blood cells and often of white blood cells and platelets. Last week at the Society of Hematologic Oncology (SOHO)'s Seventh Annual Meeting, Srdan ...
Continue reading

Fedratinib Approved for Myelofibrosis

​The FDA has now approved fedratinib (Inrebic®, Impact Biomedicines, Inc./Celgene Corporation) for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis. A myeloproliferative neoplasm, myelofibrosis can either present as a primary condition or as a secondary condition following the transformation of polycythemia vera or essential thrombocythemia. Myelofibrosis causes anemia, splenomegaly, and debilitating symptoms, and it shortens survival. "Prior to today, there was on...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.